KRON News and Press, Kronos Bio Inc. From 03/21/24

2024-03-21 13:53:23 ET InvestorPlace - Stock Market News, Stock Advice & Trading Tips Kronos Bio (NASDAQ: KRON ) just reported results for the fourth quarter of 2023. Kronos Bio reported earnings per share of -43 cents. This was above the analyst estimate f...

2024-03-21 12:41:20 ET More on Kronos Bio Kronos cuts 21% of workforce, extends cash runway into 2H 2026 Kronos Bio streamlines leadership, cuts CMO, CSO and COO roles Seeking Alpha’s Quant Rating on Kronos Bio Historical earnings data for Kronos Bio ...

Phase 1/2 study of KB-0742 is on track to clear 80mg four-days-on, three-days-off schedule in the third quarter of 2024; topline data from expansion cohort at this schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-hum...

Weir Group plc ADR (WEGRY) is expected to report for Q4 2023 So-Young International Inc. (SY) is expected to report for quarter end 2023-12-31 Atara Biotherapeutics Inc. (ATRA) is expected to report $-0.61 for Q4 2023 Adyen NV ADR (ADYEY) is expected to report for Q4 2023 Five Bel...

2024-03-07 16:37:27 ET More on Kronos Bio Kronos Bio streamlines leadership, cuts CMO, CSO and COO roles Kronos ends development of lanraplenib combo therapy for AML Seeking Alpha’s Quant Rating on Kronos Bio Historical earnings data for Kronos Bio ...

Company to assess KB-0742 at planned new dose schedule in ongoing phase 1/2 study; topline data from expansion cohort at new dose schedule expected in the first half of 2025 IND-enabling studies for KB-9558 expected to complete in 2024 with first-in-human study anticipated to commence i...

SAN MATEO, Calif. and CAMBRIDGE, Mass., March 05, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced that three abstracts have been selected for presentation at the American Association for Cancer Re...

SAN MATEO, Calif. and CAMBRIDGE, Mass., Feb. 27, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced participation in the 44 th Annual Cowen Health Care Conference, taking place March 4-6, 2024, i...

2024-01-25 08:25:37 ET More on Kronos Bio Kronos ends development of lanraplenib combo therapy for AML Kronos to cut 19% of workforce, focus on drugs KB-0742, lanraplenib Seeking Alpha’s Quant Rating on Kronos Bio Historical earnings data for Kronos Bi...

SAN MATEO, Calif., and CAMBRIDGE, Mass., Jan. 25, 2024 (GLOBE NEWSWIRE) -- Kronos Bio, Inc. (Nasdaq: KRON), a company dedicated to transforming the lives of those affected by cancer, today announced a streamlined leadership structure designed to focus on pipeline advancement and align with Kronos...